AbbVie announced a $700 million upfront payment to IGI Therapeutics for rights to ISB 2001, a trispecific antibody designed to bind three targets involved in multiple myeloma treatment. The therapy, which targets CD3 on T cells and BCMA and CD38 on tumor cells, has shown encouraging Phase 1 results with a favorable safety profile and an overall response rate of 79% in relapsed/refractory patients. With orphan drug and fast track designations, AbbVie plans to explore additional indications including autoimmune diseases. The deal includes potential milestone payments exceeding $1.2 billion and tiered royalties, forming part of a broader pharma trend advancing multi-target therapeutics to overcome resistance and enhance treatment efficacy.